According to the Zhixun Finance APP, on Monday, $AbbVie (ABBV.US)$Opening significantly lower, as of the time of publication, a sharp drop of over 12%, at $174.84.

On the news front, abbvie stated that the recently acquired Emmacladine candidate drug for treating schizophrenia did not meet key targets in a mid-stage study. The phase 2 study of Emmacladine did not reach its primary endpoint, with no statistically significant improvement in the severity of symptoms in patients with this mental health disorder in the sixth week. The company stated that it is still analyzing the research data to determine the next steps.

It is worth noting that $Bristol-Myers Squibb (BMY.US)$However, it rose by over 11%, marking the largest increase since March 2006. Analysts say that this stock may be responding to the news above abbvie.

Editor/ping